Pharmsville Co., Ltd.

Pharmsville Co., Ltd.

KKRX:318010
3,255.00
KRW
-100.00
(-2.98%)
390.79EPS
8.51P/E
25.43BMarket Cap

Total Valuation

KRW

As of June 30, 2026, Pharmsville Co., Ltd. carries a market capitalization of 25.43B, placing it among publicly traded companies globally. Its enterprise value stands at -10.20B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap25.43B
Enterprise Value-10.20B

Share Statistics

As of June 30, 2026, Pharmsville Co., Ltd. has 7.73M shares outstanding.

Shares Outstanding7.73M

Valuation Ratios

As of June 30, 2026, Pharmsville Co., Ltd. trades at a trailing price-to-earnings ratio of 8.51. The price-to-sales ratio is 2.27, and the price-to-book ratio stands at 0.38.

PE Ratio8.51
PS Ratio2.27
PB Ratio0.38
P/TBV Ratio0.39
P/FCF Ratio18.99
P/OCF Ratio16.54

Financial Position

As of June 30, 2026, Pharmsville Co., Ltd. maintains a current ratio of 23.61, meaning it holds 23.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 0.02, indicating conservative leverage, while an interest coverage ratio of -176.17 demonstrates limited ability to service its debt obligations.

Current Ratio23.61
Quick Ratio22.40
Debt / Equity0.02
Debt / EBITDA-0.10
Interest Coverage-176.17

Financial Efficiency

KRW

Over the twelve months ended June 30, 2026, Pharmsville Co., Ltd. posted a return on equity (ROE) of 4.53, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) is negative at -0.77, so the business is destroying capital rather than earning a return above its cost of capital. Return on assets (ROA) stands at 4.39, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 4.48, useful for judging operating efficiency across full business cycles. The company generates approximately 426.73M in revenue per employee across its workforce of 26.25, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.76 indicates how many times Pharmsville Co., Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Return on Equity (ROE)4.53
Return on Assets (ROA)4.39
Return on Invested Capital (ROIC)-0.77
Return on Capital Employed (ROCE)4.48
Revenue Per Employee426.73M
Employee Count26.25
Inventory Turnover2.76

Taxes

KRW

Over the twelve months ended June 30, 2026, Pharmsville Co., Ltd. recorded 1.05B in income tax expense. That works out to an effective tax rate of 25.73, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 4.07B, leaving 2.99B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

Income Tax1.05B
Effective Tax Rate25.73

Stock Price Statistics

KRW

As of the close on November 17, 2026, Pharmsville Co., Ltd.'s stock has declined approximately 5.65% over the past 52 weeks. The 50-day moving average sits at 3,492.34, while the 200-day moving average is 3,537.59.

52-Week Price Change-5.65%
50-Day Moving Average3,492.34
200-Day Moving Average3,537.59

Income Statement

KRW

Over the twelve months ended June 30, 2026, Pharmsville Co., Ltd. generated 11.20B in revenue and converted that into 2.99B in net income, yielding earnings per share of 390.79. EBITDA reached -136.01M, while operating income came in at -687.48M.

Revenue11.20B
Gross Profit7.15B
Operating Income-687.48M
Pretax Income4.07B
Net Income2.99B
EBITDA-136.01M
EBIT-687.48M
Earnings Per Share (EPS)390.79

Balance Sheet

KRW

As of June 30, 2026, Pharmsville Co., Ltd. holds 35.77B in cash and equivalents against 14.17M in total debt, resulting in a net debt position of -4.91B. Total book value stands at 66.56B, with working capital of 36.11B providing operational flexibility.

Cash & Cash Equivalents35.77B
Total Debt14.17M
Net Debt-4.91B
Equity (Book Value)66.56B
Book Value Per Share8,612.29
Working Capital36.11B

Cash Flow

KRW

Pharmsville Co., Ltd. produced 1.54B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -198.29M in capital expenditures, free cash flow totaled 1.34B - equivalent to 173.25 per share.

Operating Cash Flow1.54B
Capital Expenditures-198.29M
Free Cash Flow1.34B
FCF Per Share173.25

Margins

Over the twelve months ended June 30, 2026, Pharmsville Co., Ltd. posted a gross margin of 63.79, reflecting its pricing power and cost economics. The operating margin of -6.14 and net profit margin of 26.69 provide insight into operational efficiency.

Gross Margin63.79
Operating Margin-6.14
Pretax Margin36.30
Profit Margin26.69
EBITDA Margin-1.21

Dividends & Yields

Over the twelve months ended June 30, 2026, Pharmsville Co., Ltd. paid dividends of - - per share. The dividend payout ratio of - - indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 5.27, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 6.14, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Pharmsville Co., Ltd. shareholders.

Shareholder Yield6.14
FCF Yield5.27

Scores

As of June 30, 2026, Pharmsville Co., Ltd. has an Altman Z-Score of 10.82, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score10.82